Source comparison
CJC-1295 No DAC vs DAC vs GHRP-2: Protocol Comparison
Before running any growth hormone secretagogue protocol, understanding the kinetic and mechanistic differences between peptide classes prevents dosing errors that waste compounds or create unwanted side effects. CJC-1295 No DAC GHRH analog. Stimulates endogeno
This comparison does not assign a generated winner or score.
- Before running any growth hormone secretagogue protocol, understanding the kinetic and mechanistic differences between peptide classes prevents dosing errors that waste compounds or create unwanted side effects.
- CJC-1295 No DAC
- GHRH analog. Stimulates endogenous GH pulse
- ~30 minutes (serum), 2–4 hours (effect)
- Every 3–5 days
- 100–200mcg per injection
- Pairs with GHRP-2 or GHRP-6 for amplified pulse
- Best for maintaining natural pulsatility without daily dosing. Receptor-friendly
- CJC-1295 with DAC
- GHRH analog with Drug Affinity Complex modification
- 6–8 days
- Once weekly
- 500–1000mcg per injection
- Sustained elevation. Less synergy needed
- Convenient but higher desensitization risk. Continuous elevation may suppress endogenous rhythm
- GHRP-2
- Ghrelin mimetic. Stimulates GH via ghrelin receptor
- ~30 minutes
- 1–3 times daily
- 100–300mcg per dose
- Stacks with CJC-1295 No DAC for synergistic GH release
- Provides immediate pulse. Requires frequent dosing but avoids pituitary downregulation
- Ipamorelin
- Selective ghrelin receptor agonist
- ~2 hours
- 1–2 times daily
- 200–300mcg per dose
- Minimal cortisol/prolactin spike
- Cleaner side effect profile than GHRP-2. No hunger spike
- The key insight from this table: CJC-1295 No DAC and GHRP-2 work through complementary pathways (GHRH receptor vs ghrelin receptor) and are often stacked in research protocols to produce synergistic GH release exceeding what either peptide achieves alone. A common advanced protocol uses 100mcg CJC-1295 No DAC plus 200mcg GHRP-2 injected simultaneously every 3 days before bed. This combination produced mean IGF-1 increases of 35–50% in clinical cohorts without the appetite stimulation (from ghrelin agonism) or cortisol elevation (from non-selective GHRPs) that complicates long-term use.